Houston company wins AHA competition for pediatric heart valve design

winner, winner

Houston-based PolyVascular won the American Heart Association’s annual Health Tech Competition. Courtesy of TMC Innovation

Houston-based PolyVascular, which develops minimally invasive solutions for children with congenital heart disease, was named the overall winner of the American Heart Association’s annual Health Tech Competition earlier this month.

The company was founded in 2014 by Dr. Henri Justino and Daniel Harrington and was part of TMCi's 2017 medical device cohort. It is developing the first polymer-based transcatheter pulmonary valve designed specifically for young children, allowing for precise sizing and redilation as the child grows while also avoiding degradation. PolyVascular has completed preclinical studies and is working toward regulatory submissions, an early feasibility study and its first-in-human clinical trial thanks to a recent SBIR grant from the National Heart, Lung, and Blood Institute.

With the new AHA honor, PolyVascular will be invited to join the association’s Center for Health Technology & Innovation Innovators’ Network, which connects entrepreneurs, providers and researchers to share and advance innovation in cardiovascular and brain health.

“This is a tremendous honor for PolyVascular—we’re especially proud to bring hope to families and children living with congenital heart defects,” Justino said in a news release. “Our technology—a minimally invasive valve that can be expanded over time to grow with the child—has the potential to dramatically reduce the need for repeated open-heart surgeries.”

The Health Tech Competition is a live forum for health care innovators to present their digital solutions for treating or preventing cardiovascular diseases and stroke.

Finalists from around the world addressed heart failure, hypertension, congenital heart defects and other issues that exist in cardiovascular, brain and metabolic health. Solutions were evaluated on the criteria of validity, scientific rigor and impact.

The judges included Texas-based Dr. Eric D. Peterson, professor of medicine in the division of cardiology at UT Southwestern Medical Center, and Dr. Asif Ali, clinical associate professor of cardiovascular medicine at the University of Texas Medical School in Houston and director at Cena Research Institute.

According to the American Heart Association, nearly half of U.S. adults live with some form of cardiovascular disease or stroke.

“The American Heart Association plays a pivotal role in advancing innovative care pathways, and we’re excited that our solution aligns with its guidelines and mission,” Justino said in a news release. “It’s time these life-changing technologies reach the youngest patients, just as they already do for adults.”

From Your Site Articles
CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding. Photo via Getty Images

University of Houston-founded company secures $2.5M in NIH grant funding

all in the timing

You could say that the booming success of Houston biotech company CellChorus owes very much to auspicious TIMING. Those six letters stand for Time-lapse Imaging Microscopy In Nanowell Grids, a platform for dynamic single-cell analysis.

This week, CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding from the National Center for Advancing Translational Sciences (NCATS) at the National Institute of Health. A $350,000 Phase I grant is already underway. Once predetermined milestones are achieved, this will lead to a two-year $2.1 million Phase II grant.

The TIMING platform was created by UH Single Cell Lab researchers Navin Varadarajan and Badri Roysam. TIMING generates high-throughput in-vitro assays that quantitatively profile interactions between cells on a large scale, particularly what happens when immune cells confront target cells. This has been especially useful in the realm of immuno-oncology, where it has demonstrated its power in designing novel therapies, selecting lead candidates for clinical trials and evaluating the potency of manufactured cells.

“By combining AI, microscale manufacturing and advanced microscopy, the TIMING platform yields deep insight into cellular behaviors that directly impact human disease and new classes of therapeutics,” says Rebecca Berdeaux, chief scientific officer at CellChorus. “The generous support of NCATS enables our development of computational tools that will ultimately integrate single-cell dynamic functional analysis of cell behavior with intracellular signaling events.”

Houston’s CellChorus Innovation Lab supports both the further development of TIMING and projects for early-access customers. Those customers include top-25 biopharmaceutical companies, venture-backed biotechnology companies, a leading comprehensive cancer center and a top pediatric hospital, says CEO Daniel Meyer.

CellChorus’s publications include papers written in collaboration with researchers from the Baylor College of Medicine, Houston Methodist, MD Anderson, Texas Children’s Hospital, the University of Texas and UTHealth in journals including Nature Cancer, Journal of Clinical Investigation and The Journal for ImmunoTherapy of Cancer.

The new Small Business Technology Transfer (STTR) award will specifically support the development of a scalable integrated software system conceived with the goal of analyzing cells that are not fluorescently labeled. This label-free analysis will be based on new AI and machine learning (ML) models trained on tens of millions of images of cells.

“This is an opportunity to leverage artificial intelligence methods for advancing the life sciences,” says Roysam. “We are especially excited about its applications to advancing cell-based immunotherapy to treat cancer and other diseases.”

The Houston-born-and-bred company couldn’t have a more appropriate home, says Meyer.

“Houston is a premier location for clinical care and the development of biotechnology and life sciences technologies. In particular, Houston has established itself as a leader in the development and delivery of immune cell-based therapies,” the CEO explains. “As a spin-out from the Single Cell Lab at the University of Houston, we benefit from working with world-class experts at local institutions.”

In May, the company received a similar $2.5 million SBIR grant from NCATS at the NIH. Also this summer, CellChorus's technology was featured in Nature Cancer.

This uniquely Houston technology is an AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement. Photo via Getty Images

University of Houston lab reports breakthrough in cancer-detecting technology

making moves

T-cell immunotherapy is all the rage in the world of fighting cancer. A Houston company’s researchers have discovered a new subset of T cells that could be a game changer for patients.

CellChorus is a spinoff of Navin Varadarajan’s Single Cell Lab, part of the University of Houston’s Technology Bridge. The lab is the creator of TIMING, or Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visual AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement.

Last month, Nature Cancer published a paper co-authored by Varadarajan entitled, “Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling.”

“Our results showed that a subset of T cells, labeled as CD8-fit T cells, are capable of high motility and serial killing, found uniquely in patients with clinical response,” says first author and recent UH graduate Ali Rezvan in Nature Cancer.

Besides him and Varadarajan, contributors hail from Baylor College of Medicine/Texas Children’s Hospital, MD Anderson Cancer Center, Kite Pharma, and CellChorus itself.

The team identified the CD80-fit T cells using TIMING to examine interactions between T cells and tumor cells across thousands of individual cells. They were able to integrate the results using single-cell RNA sequencing data.

T-cell therapy activates a patient’s own immune system to fight cancer cells, but not every patient responds favorably to it. Identifying CD8-fit cells could be the key to manufacturing clinical response even in those for whom immunotherapy hasn’t been effective.

“This work illustrates the excellence of graduate students Ali Rezvan and Melisa Montalvo; and post-doctoral researchers Melisa Martinez-Paniagua and Irfan Bandey among others,” says Varadarajan in a statement.

Earlier last month, CellChorus recently received a $2.5 million SBIR grant. The money allows the company to share TIMING more widely, facilitating even more landmark discoveries like CD8-fit cells.

CellChorus created a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. Photo via Getty Images

Houston health tech startup scores $2.5M SBIR grant to advance unique cell therapy AI technology

fresh funding

A Houston biotech company just announced a new award of $2.5 million.

CellChorus, a spinoff of the Single Cell Lab at the University of Houston, announced the fresh funding, which comes from an SBIR (Small Business Innovation Research) grant from the National Institute of Health (NIH) through its National Center for Advancing Translational Sciences (NCATS).

CellChorus is the business behind a technology called TIMING, which stands for Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. This more in-depth knowledge of immune cells could be instrumental in developing novel therapies in countless disorders, including cancers and infectious diseases.

“While many cell therapies have been approved and are in development, the industry needs an integrated analytical platform that provides a matrix of functional readouts, including cell phenotype and metabolism on the same cells over time,” Rebecca Berdeaux, vice president of science at CellChorus, says in a press release. “We are grateful to NCATS for its support of the development of application-specific kits that apply dynamic, functional single-cell analysis of immune cell phenotype and function. The product we will develop will increase the impact of these therapies to improve the lives of patients.”

A two-year, $2.1 million Phase II grant will begin after the company achieves predetermined milestones under a $350,000 Phase I grant that is currently taking place. As Berdeaux explained, the funds will be used to develop TIMING kits which will manufacture analytics that provide end-users with rapid, specific and predictive results to accelerate translational research and the development and manufacture of more effective cell therapies.

TIMING is more than a great idea whose time has yet to come. It has already been proven in great depth. In fact, last June, CellChorus CEO Daniel Meyer told InnovationMap that he was initially attracted to the technology because it was “very well validated.” At the time, CellChorus had just announced a $2.3 million SBIR Fast-Track grant from the National Institute of General Medical Sciences. The company also went on to win an award in the Life Science category of the 2023 Houston Innovation Awards.

That confirmation of success comes from more than 200 peer-reviewed papers that describe myriad cell types and types of therapy, all of which used data from TIMING assays. TIMING data has benefited industry leaders in everything from research and clinical development to manufacturing. With the new grant, TIMING will become more widely available to scientists making important discoveries relating to the inner workings of the cells that drive our immunity.

CellChorus, a biotech startup operating out of the University of Houston Technology Bridge, has secured fresh funding. Photo via Getty Images

Houston biotech startup secures $2.3M grant

cha-ching

They say it’s all in the timing. For CellChorus, it’s all in the TIMING. That’s Time-lapse Imaging Microscopy In Nanowell Grids. TIMING is a visual AI program that evaluates cell activation, killing and movement, which allows scientists to better understand how cells function.

The technology is important to the development of novel therapies in the realms of oncology, infectious diseases, and countless other disorders and diseases. By allowing scientists to observe those maladies at their roots, it will enable them to create, and ultimately deliver new medications and other therapies faster, at lower cost, and with a higher success rate.

CellChorus is a spinoff of the Single Cell Lab at the University of Houston. Part of UH’s Technology Bridge, CEO Daniel Meyer connected with co-founder and leader of Single Cell Lab, Navin Varadarajan, through co-founder Laurence Cooper.

“The company had been established, but there were limited operations,” recalls Meyer during a phone call with InnovationMap.

That was the fall of 2020. Now, the team has just announced a $2.3 million SBIR (Small Business Innovation Research) Fast-Track grant from the National Institute of General Medical Sciences.

“This funding will support development of a product offering that builds on the success of our early access laboratory,” Cooper said in a press release. “As the next frontier of cellular analysis, dynamic single-cell analysis will increase the impact that immunotherapies have in improving the lives of patients.”

Meyer is based in the Bay Area, but the rest of the team is in Houston. Meyer has a proven track record as an investor and early stage entrepreneur in life sciences companies, including work as COO of Genospace, which was acquired by HCA Healthcare.

Meyer says that what attracted him to CellChorus was a combination of a clear need for the technology and the fact that it was “very well validated.“

“Developers of immunotherapies need better functional data earlier so that they can develop and deliver better therapies,” he explains.

Another aspect of its appeal was the fact that more than 10 publications featured data from the TIMING platform.

“We’ve had both large and small biopharmas publish data,” says Meyer. “That’s important as well because it shows there’s applicability in both nonprofit and for-profit research.”

Though Meyer himself doesn’t currently live in Houston, he recognizes its importance to CellChorus. He says that it can be difficult for an early stage company to find appropriate lab space, so Technology Bridge was of exceptional importance for CellChorus. Since opening the lab a year and a half ago, Varadarajan and his team have been busy.

“Example projects we have completed include understanding mechanism of action for cell therapy products, selecting lead candidates for T cell engagers, identifying biomarkers of response to cell therapies, and quantifying potency and viability for cell therapy manufacturing technologies,” says Meyer.

And now, CellChorus is collaborating with leaders in the industry.

“These include top-25 biopharmaceutical companies and promising venture-backed biotechnology companies, as well as leading not-for-profit research institutions,” says Meyer in a press release. It’s clear that the TIMING is right for CellChorus to excel.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston climbs to top 10 spot on North American tech hubs index

tech report

Houston already is the Energy Capital of the World, and now it’s gaining ground as a tech hub.

On Site Selection magazine’s 2026 North American Tech Hub Index, Houston jumped to No. 10 from No. 16 last year. The index relies on data from Site Selection as well as data from CBRE, CompTIA and TeleGeography to rank the continent’s tech hotspots. The index incorporates factors such as internet connectivity, tech talent and facility projects for tech companies.

In 2023, the Greater Houston Partnership noted the region had “begun to receive its due as a prominent emerging tech hub, joining the likes of San Francisco and Austin as a major player in the sector, and as a center of activity for the next generation of innovators and entrepreneurs.”

The Houston-area tech sector employs more than 230,000 people, according to the partnership, and generates an economic impact of $21.2 billion.

Elsewhere in Texas, two other metros fared well on the Site Selection index:

  • Dallas-Fort Worth nabbed the No. 1 spot, up from No. 2 last year.
  • Austin rose from No. 8 last year to No. 7 this year.

San Antonio slid from No. 18 in 2025 to No. 22 in 2026, however.

Two economic development officials in DFW chimed in about the region’s No. 1 ranking on the index:

  • “This ranking affirms what we’ve long seen on the ground — Dallas-Fort Worth is a top-tier technology and innovation center,” said Duane Dankesreiter, senior vice president of research and innovation at the Dallas Regional Chamber. “Our region’s scale, talent base, and diverse strengths … continue to set DFW apart as a national leader.”
  • “Being recognized as the top North American tech hub underscores the strength of the entire Dallas-Fort Worth region as a center of innovation and next-generation technology,” said Robert Allen, president and CEO of the Fort Worth Economic Development Partnership.

While not directly addressing Austin’s Site Selection ranking, Thom Singer, CEO of the Austin Technology Council, recently pondered whether Silicon Hills will grow “into the kind of community that other cities study for the right reasons.”

“Austin tech is not a club. It is not a scene. It is not a hashtag, a happy hour, or any one place or person,” Singer wrote on the council’s blog. “Austin tech is an economic engine and a global brand, built by thousands of people who decided to take a risk, build something, hire others, and be part of a community that is still young enough to reinvent itself.”

South of Austin, Port San Antonio is driving much of that region’s tech activity. Occupied by more than 80 employers, the 1,900-acre tech and innovation campus was home to 18,400 workers in 2024 and created a local economic impact of $7.9 billion, according to a study by Zenith Economics.

“Port San Antonio is a prime example of how innovation and infrastructure come together to strengthen [Texas’] economy, support thousands of good jobs, and keep Texas competitive on the global stage,” said Kelly Hancock, the acting state comptroller.

14 Houston startups starting 2026 with fresh funding

cha-ching

Houston startups closed out the last half of 2025 with major funding news.

Here are 14 Houston companies—from groundbreaking energy leaders to growing space startups—that secured funding in the last six months of the year, according to reporting by InnovationMap and our sister site, EnergyCapitalHTX.com.

Did we miss a funding round? Let us know by emailing innoeditor@innovationmap.com.

Fervo Energy

Fervo Energy has closed an oversubscribed Series E. Photo via Fervo Energy

Houston-based geothermal energy company Fervo Energy closed an oversubscribed $462 million series E funding round, led by new investor B Capital, in December.

The company also secured $205.6 million from three sources in June.

“Fervo is setting the pace for the next era of clean, affordable, and reliable power in the U.S.,” Jeff Johnson, general partner at B Capital, said in a news release.

The funding will support the continued buildout of Fervo’s Utah-based Cape Station development, which is slated to start delivering 100 MW of clean power to the grid beginning in 2026. Cape Station is expected to be the world's largest next-generation geothermal development, according to Fervo. The development of several other projects will also be included in the new round of funding. Continue reading.

Square Robot

Houston robotics co. unveils new robot that can handle extreme temperatures

Square Robot's technology eliminates the need for humans to enter dangerous and toxic environments. Photo courtesy of Square Robot

Houston- and Boston-based Square Robot Inc. announced a partnership with downstream and midstream energy giant Marathon Petroleum Corp. (NYSE: MPC) last month.

The partnership came with an undisclosed amount of funding from Marathon, which Square Robot says will help "shape the design and development" of its submersible robotics platform and scale its fleet for nationwide tank inspections. Continue reading.

Eclipse Energy

Eclipse Energy and Weatherford International are expected to launch joint projects early this year. Photo courtesy of Eclipse Energy.

Oil and gas giant Weatherford International (NASDAQ: WFRD) made a capital investment for an undisclosed amount in Eclipse Energy in December as part of a collaborative partnership aimed at scaling and commercializing Eclipse's clean fuel technology.

According to a release, joint projects from the two Houston-based companies are expected to launch as soon as this month. The partnership aims to leverage Weatherford's global operations with Eclipse Energy's pioneering subsurface biotechnology that converts end-of-life oil fields into low-cost, sustainable hydrogen sources. Continue reading.

Venus Aerospace 

Lockheed Martin Ventures says it's committed to helping Houston-based Venus Aerospace scale its technology. Photo courtesy Venus Aerospace

Venus Aerospace, a Houston-based startup specializing in next-generation rocket engine propulsion, has received funding from Lockheed Martin Ventures, the investment arm of aerospace and defense contractor Lockheed Martin, for an undisclosed amount, the company announced in November. The product lineup at Lockheed Martin includes rockets.

The investment follows Venus’ successful high-thrust test flight of its rotating detonation rocket engine (RDRE) in May. Venus says it’s the only company in the world that makes a flight-proven, high-thrust RDRE with a “clear path to scaled production.”

Venus says the Lockheed Martin Ventures investment reflects the potential of Venus’ dual-use technology for defense and commercial uses. Continue reading.

Koda Health

Tatiana Fofanova and Dr. Desh Mohan, founders of Koda Health, which recently closed a $7 million series A. Photo courtesy Koda Health.

Houston-based digital advance care planning company Koda Health closed an oversubscribed $7 million series A funding round in October.

The round, led by Evidenced, with participation from Mudita Venture Partners, Techstars and Texas Medical Center, will allow the company to scale operations and expand engineering, clinical strategy and customer success, according to a news release.

The company shared that the series A "marks a pivotal moment," as it has secured investments from influential leaders in the healthcare and venture capital space. Continue reading.

Hertha Metals

U.S. Rep. Morgan Luttrell, a Magnolia Republican, and Hertha Metals founder and CEO Laureen Meroueh toured Hertha’s Conroe plant in August. Photo courtesy Hertha Metals/Business Wire.

Conroe-based Hertha Metals, a producer of substantial steel, hauled in more than $17 million in venture capital from Khosla Ventures, Breakthrough Energy Fellows, Pear VC, Clean Energy Ventures and other investors.

The money was put toward the construction and the launch of its 1-metric-ton-per-day pilot plant in Conroe, where its breakthrough in steelmaking has been undergoing tests. The company uses a single-step process that it claims is cheaper, more energy-efficient and equally as scalable as conventional steelmaking methods. The plant is fueled by natural gas or hydrogen.

The company, founded in 2022, plans to break ground early this year on a new plant. The facility will be able to produce more than 9,000 metric tons of steel per year. Continue reading.

Helix Earth Technologies, Resilitix Intelligence and Fluxworks Inc.

Helix Earth's technology is estimated to save up to half of the net energy used in commercial air conditioning, reducing both emissions and costs for operators. Photo via Getty Images

Houston-based Helix Earth Technologies, Resilitix Intelligence and Fluxworks Inc. each secured $1.2 million in federal funding through the Small Business Innovation Research (SBIR) Phase II grant program this fall.

The three grants from the National Scienve foundation officially rolled out in early September 2025 and are expected to run through August 2027, according to the NSF. The SBIR Phase II grants support in-depth research and development of ideas that showed potential for commercialization after receiving Phase I grants from government agencies.

However, congressional authority for the program, often called "America's seed fund," expired on Sept. 30, 2025, and has stalled since the recent government shutdown. Continue reading.

Solidec Inc. (pre-seed)

7 innovative startups that are leading the energy transition in Houston

Houston-based Solidec was founded around innovations developed by Rice University associate professor Haotian Wang (far left). Photo courtesy Greentown Labs.

Solidec, a Houston startup that specializes in manufacturing “clean” chemicals, raised more than $2 million in pre-seed funding in August.

Houston-based New Climate Ventures led the oversubscribed pre-seed round, with participation from Plug and Play Ventures, Ecosphere Ventures, the Collaborative Fund, Safar Partners, Echo River Capital and Semilla Climate Capital, among other investors. Continue reading.

Molecule

Sameer Soleja is the founder and CEO of Molecule, which just closed its series B round. Photo courtesy of Molecule Software.

Houston-based energy trading risk management (ETRM) software company Molecule completed a successful series B round for an undisclosed amount, according to a July 16 release from the company.

The raise was led by Sundance Growth, a California-based software growth equity firm. Sameer Soleja, founder and CEO of Molecule, said in the release that the funding will allow the company to "double down on product innovation, grow our team, and reach even more markets." Continue reading.

Rarefied Studios, Solidec Inc. and Affekta

Houston startups were named among the nearly 300 recipients that received a portion of $44.85 million from NASA to develop space technology this fall. Photo via NASA/Ben Smegelsky

Houston-based Rarefied Studios, Solidec Inc. and Affekta were granted awards from NASA this summer to develop new technologies for the space agency.

The companies are among nearly 300 recipients that received a total agency investment of $44.85 million through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I grant programs, according to NASA.

Each selected company received $150,000 and, based on their progress, will be eligible to submit proposals for up to $850,000 in Phase II funding to develop prototypes. The SBIR program lasts for six months and contracts small businesses. Continue reading.

Intuitive Machines 

Intuitive Machines expects to begin manufacturing and flight integration on its orbital transfer vehicle as soon as 2026. Photo courtesy Intuitive Machines.

Houston-based Intuitive Machines secured a $9.8 million Phase II government contract for its orbital transfer vehicle in July.

The contract was expected to push the project through its Critical Design Review phase, which is the final engineering milestone before manufacturing can begin, according to a news release from the company. Intuitive Machines reported that it expected to begin manufacturing and flight integration for its orbital transfer vehicle as soon as this year, once the design review is completed.

The non-NASA contract is for an undisclosed government customer, which Intuitive Machines says reinforces its "strategic move to diversify its customer base and deliver orbital capabilities that span commercial, civil, and national security space operations." Continue reading.

NRG inks new virtual power plant partnership to meet surging energy demands

Powering Up

Houston-based NRG Energy recently announced a new long-term partnership with San Francisco-based Sunrun that aims to meet Texas’ surging energy demands and accelerate the adoption of home battery storage in Texas. The partnership also aligns with NRG’s goal of developing a 1-gigawatt virtual power plant by connecting thousands of decentralized energy sources by 2035.

Through the partnership, the companies will offer Texas residents home energy solutions that pair Sunrun’s solar-plus-storage systems with optimized rate plans and smart battery programming through Reliant, NRG’s retail electricity provider. As new customers enroll, their stored energy can be aggregated and dispatched to the ERCOT grid, according to a news release.

Additionally, Sunrun and NRG will work to create customer plans that aggregate and dispatch distributed power and provide electricity to Texas’ grid during peak periods.

“Texas is growing fast, and our electricity supply must keep pace,” Brad Bentley, executive vice president and president of NRG Consumer, said in the release. “By teaming up with Sunrun, we’re unlocking a new source of dispatchable, flexible energy while giving customers the opportunity to unlock value from their homes and contribute to a more resilient grid

Participating Reliant customers will be paid for sharing their stored solar energy through the partnership. Sunrun will be compensated for aggregating the stored capacity.

“This partnership demonstrates the scale and strength of Sunrun’s storage and solar distributed power plant assets,” Sunrun CEO Mary Powell added in the release. “We are delivering critical energy infrastructure that gives Texas families affordable, resilient power and builds a reliable, flexible power plant for the grid.”

In December, Reliant also teamed up with San Francisco tech company GoodLeap to bolster residential battery participation and accelerate the growth of NRG’s virtual power plant network in Texas.

In 2024, NRG partnered with California-based Renew Home to distribute hundreds of thousands of VPP-enabled smart thermostats by 2035 to help households manage and lower their energy costs. At the time, the company reported that its 1-gigawatt VPP would be able to provide energy to 200,000 homes during peak demand.

---

This article originally appeared on EnergyCapitalHTX.com.

View All Listings